Zhong Ji Longevity Science Group Limited (0767) AI Stock Analysis

• Market Cap: HK$311.96M
• Dividend Yield: N/A
• Average Volume (3M): 487.89K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.12
• Revenue Growth: 121.54%
• EPS Growth: -8360.00%
• Country: HK
• Employees: 55
• Sector: Financial
• Sector Strength: 70
• Industry: Financial - Credit Services
• EPS (TTM): -0.02
• Shares Outstanding: 636,654,300
• 10 Day Avg. Volume: 325,210
• 30 Day Avg. Volume: 487,892
• PEG Ratio: <0.01
• Price to Book (P/B): 0.31
• Price to Sales (P/S): 0.68
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: HK$0.49 ▼(-3.92% Downside)

The overall stock score of 50 reflects a combination of mixed financial performance, neutral technical indicators, and challenging valuation metrics. The company's strong balance sheet is offset by cash flow issues and negative profitability, while technical analysis suggests a lack of strong momentum. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates successful market penetration and product acceptance, supporting long-term business expansion.

Debt-Free Balance Sheet

A debt-free balance sheet provides financial flexibility and reduces risk, allowing the company to invest in growth opportunities without financial strain.

Strategic Partnerships

Partnerships expand distribution channels and market presence, potentially leading to increased sales and a stronger competitive position.

Negative Factors

Cash Flow Challenges

Persistent cash flow issues can hinder operational sustainability and limit the company's ability to fund growth initiatives.

Declining Equity and Assets

A decline in equity and assets may indicate weakening financial health, potentially impacting the company's ability to invest in future growth.

Profitability Challenges

Negative profitability margins suggest cost management issues, which could affect long-term financial viability if not addressed.

Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model

Company Description

Zhong Ji Longevity Science Group Limited, an investment holding company, engages in the money lending business in Hong Kong and Mainland China. The company is involved in the provision of diagnostic consultation, and health and medical testing and checking services, as well as distribution of healthcare supplements. It also engages in the holding of equity investments; investment in short and long-term financial assets; provision of financial and investment consulting activities; and investment in properties. In addition, it offers health consulting services; and trades in medical products. The company was formerly known as Asia Pacific Silk Road Investment Company Limited and changed its name to Zhong Ji Longevity Science Group Limited in March 2021. Zhong Ji Longevity Science Group Limited was incorporated in 1994 and is headquartered in Causeway Bay, Hong Kong.

How the Company Makes Money

Zhong Ji Longevity Science Group Limited generates revenue primarily through the sale of its health supplements and traditional Chinese medicine products. The company operates a multi-channel distribution model, which includes direct sales through its online platforms, partnerships with healthcare providers, and retail distribution in pharmacies and wellness stores. Additionally, revenue is supplemented by research and development collaborations with other healthcare entities and institutions, allowing for the commercialization of innovative health solutions. The company's strategic partnerships with distributors and healthcare providers enhance its market reach, contributing significantly to its overall revenue.

Zhong Ji Longevity Science Group Limited Financial Statement Overview

Summary

Zhong Ji Longevity Science Group Limited shows a mixed financial picture. The income statement reflects growth but also highlights significant volatility and profitability challenges. The balance sheet is strong with no current debt, but overall asset and equity levels have been declining. Cash flow issues, particularly with operating and free cash flow, pose a concern for sustainable operations.

Income Statement

The company's income statement shows moderate performance with significant volatility. The gross profit margin is high due to zero cost of goods sold, but the net profit margin is negative, reflecting high expenses relative to revenue. Revenue growth is strong over the last year, but historical data shows inconsistency in revenue and profitability.

Balance Sheet

The balance sheet is relatively strong with no debt in the latest year, resulting in a favorable debt-to-equity ratio. High equity ratio indicates stability, but declining stockholders' equity and total assets over recent years highlight potential risks.

Cash Flow

Cash flow analysis reveals challenges with operating cash flow consistently underperforming relative to net income. Free cash flow growth is non-existent due to zero free cash flow in the latest year, which indicates potential cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	174.06M	168.63M	64.99M	89.44M	62.98M	81.41M
Gross Profit	174.06M	57.41M	56.28M	79.41M	49.40M	71.83M
EBITDA	-17.56M	-23.10M	13.02M	15.99M	16.13M	-11.89M
Net Income	-46.43M	-34.73M	2.31M	-904.00K	6.05M	-11.49M
Balance Sheet
Total Assets	509.39M	525.63M	509.25M	484.84M	517.50M	478.24M
Cash, Cash Equivalents and Short-Term Investments	30.04M	47.84M	81.08M	60.07M	19.44M	40.80M
Total Debt	12.77M	19.11M	20.20M	11.76M	12.93M	8.70M
Total Liabilities	77.85M	125.49M	78.79M	63.99M	46.78M	23.35M
Stockholders Equity	404.98M	373.42M	403.40M	393.83M	443.75M	428.83M
Cash Flow
Free Cash Flow	-106.77M	-61.76M	15.28M	11.08M	-40.51M	-192.89M
Operating Cash Flow	-104.97M	-61.05M	15.28M	12.11M	-39.62M	-191.54M
Investing Cash Flow	10.45M	11.47M	382.00K	16.59M	2.91M	70.11M
Financing Cash Flow	20.18M	15.17M	6.02M	-7.45M	3.44M	-1.43M

Zhong Ji Longevity Science Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0767, the sentiment is Negative. The current price of 0.51 is above the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.52, and above the 200-day MA of 0.51, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.45 is Neutral, neither overbought nor oversold. The STOCH value of 39.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0767.

Zhong Ji Longevity Science Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1669	71 Outperform	HK$360.00M	7.35	5.24%	5.43%	-1.47%	2.86%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
6866	64 Neutral	HK$430.70M	7.13	2.75%	4.88%	-12.94%	-15.93%
1563	59 Neutral	HK$279.00M	20.63	0.49%	―	8.77%	-76.88%
0605	53 Neutral	HK$186.14M	6.19	4.83%	―	-25.74%	―
0767	50 Neutral	HK$311.96M	-5.79	-11.40%	―	121.54%	-8360.00%

Zhong Ji Longevity Science Group Limited Corporate Events

Zhong Ji Longevity Science Delays Circular on Major Cell Lab Acquisition

Zhong Ji Longevity Science Group Limited, a Hong Kong-listed longevity and life-sciences company focusing on cellular technologies and related healthcare applications, is pursuing an expansion of its interests through the proposed acquisition of 25% of Asian Integrated Cell Laboratory Limited, to be funded via the issue of convertible notes under a specific mandate. The company has announced a further delay in sending a shareholder circular detailing this major and connected transaction, pushing the expected dispatch date from 16 January 2026 to on or before 9 February 2026, as additional time is needed to prepare and finalise required information; the postponement may slightly extend the timetable for shareholder approval and completion but does not alter the transaction’s proposed structure or strategic intent.

The most recent analyst rating on (HK:0767) stock is a Sell with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.

Zhong Ji Longevity Science Group Delays Circular on Cell Lab Stake Acquisition

Zhong Ji Longevity Science Group Limited has announced a delay in sending to shareholders a circular relating to its proposed major and connected transaction to acquire 25% of the issued share capital of Asian Integrated Cell Laboratory Limited, which will involve the issuance of convertible notes under a specific mandate. The circular, originally expected to be dispatched on or before 22 December 2025, will now be sent on or before 16 January 2026 to allow more time to prepare and finalise required information, potentially extending the timetable for shareholder approval and completion of the acquisition but not altering the substance of the proposed deal.

The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.

Zhong Ji Longevity Science Group Announces Board Reshuffle

Zhong Ji Longevity Science Group Limited announced significant changes in its board composition, effective November 27, 2025. Mr. Lee See Barry has resigned as an independent non-executive director to focus on personal and business commitments, while Ms. Wang Huijuan has been appointed as his replacement. Additionally, Mr. Huang Jiang has been appointed as the chairperson of the audit committee. These changes are expected to bring fresh perspectives and expertise to the company’s governance, potentially impacting its strategic direction and stakeholder relations.

The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.

Zhong Ji Longevity Science Group Announces Board and Committee Structure

Zhong Ji Longevity Science Group Limited has announced the composition of its board of directors and the roles within various committees. This announcement outlines the leadership structure, which includes executive, non-executive, and independent non-executive directors, and highlights the company’s commitment to robust governance practices. The detailed roles within committees such as Audit, Nomination, Remuneration, Risk Management, and Share Award reflect the company’s strategic focus on comprehensive oversight and stakeholder engagement.

The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.

Zhong Ji Longevity Science Group Faces Board Diversity Challenge Amid Leadership Changes

Zhong Ji Longevity Science Group Limited announced the resignation of two executive directors, Mr. Yan Yifan and Ms. Cao Xie Qiong, with Mr. Yan Li stepping in as the new CEO. The company faces a compliance issue due to a lack of gender diversity on its board, as required by the Hong Kong Stock Exchange’s Listing Rules. Efforts are underway to appoint a female director by January 2026 to meet these requirements, reflecting the company’s commitment to enhancing board diversity.

The most recent analyst rating on (HK:0767) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.